

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

LIGAND PHARMACEUTICALS INC
Form 8-K
March 30, 2007

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2007

LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of incorporation)

000-20720
(Commission File Number)

10275 SCIENCE CENTER DRIVE,
SAN DIEGO, CALIFORNIA
(Address of principal executive offices)

(858) 550-7500
(Registrant's telephone number, including area code)

77-0160744
(I.R.S. Employer Identification No.)

92121-1117
(Zip Code)

ITEM 8.01 OTHER EVENTS.

Ligand Pharmaceuticals Incorporated (the "Company") has been informed today by NASDAQ that the ex-dividend date with respect to its \$2.50 per share special dividend will be April 3, 2007. The special dividend is payable on

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 8-K

April 19, 2007 to shareholders of record of the Company's common stock on April 5, 2007.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned.

LIGAND PHARMACEUTICALS INCORPORATED

Date: March 30, 2007

By: /s/ Charles S. Berkman
Name: Charles S. Berkman
Title: Assoc. General Counsel, Chief Patent Counsel
and Secretary